Printer Friendly

BCM-95 curcumin as effective as prescription drug in rheumatoid arthritis.

BCM-95, a patented, high bioavailability curcumin, was found to be equal to the prescription rheumatoid arthritis drug, diclofenac sodium, according to a recent study. The clinical trial followed 45 subjects, randomized to three groups, for 8 weeks. Group one received dictofenac sodium, 50 mg, twice daily; group two received 500 mg BCM-95 high absorption curcumin twice daily; and group three received both diclofenac sodium and BCM-95 curcumin. In the BCM-95 curcumin groups, there were no dropouts due to adverse effects, but in the diclofenac sodium group, 14% withdrew due to adverse effects.

In the Disease Activity Score (DAS)28 assessment, which includes analysis of joint swelling and pain, BCM-95 curcumin had the highest impact for reducing disease symptoms, followed by BCM-95 curcumin with diclofenac sodium, with the diclofenac sodium-alone group third. However, though the numbers were higher in the BCM95 group, none of the differences between the drug and curcumin group were statistically significant in terms of effectiveness.

The BCM-95 group showed improvement over others in reducing C-reactive protein (CRP) a measure of chronic inflammation, and antistreptococcal antibodies (ASO) titers, which are associated with severity of RA activity. For further information: www.BCM95.com
COPYRIGHT 2012 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Highlights
Publication:Nutraceuticals World
Article Type:Clinical report
Date:Jun 1, 2012
Words:194
Previous Article:Vegan-friendly high vitamin D mushroom powder.
Next Article:Kamut khorasan wheat focus of phase II study.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters